Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Myelodysplastic Syndromes
•
Rheumatology
•
Hematology
•
General Rheumatology
•
Relapsing polychondritis
•
Dermatology
•
VEXAS
In older male patients with a history of underlying autoimmune disease, what clinical manifestations would prompt you to evaluate for VEXAS Syndrome?
Answer from: at Academic Institution
Hello!!!Skin lesions, elevated MCV, elevated inflammatory markers.
Sign In
or
Register
to read more
30894
Related Questions
How do you approach recurrent migratory superficial thrombophlebitis in a patient with a negative malignancy workup and low-titer anticardiolipin antibodies?
In an infant whose mother resumes TNF inhibitor therapy (e.g., adalimumab, infliximab, certolizumab) after delivery and is breastfeeding, do you recommend delaying live vaccinations?
How do you approach a patient with high titer ANA and a new diagnosis of ITP, but no other signs or symptoms suggestive of active rheumatologic disease?
What is your approach to treatment of airway involvement, such as recurrent bronchial stenosis, in relapsing polychondritis?
Is there any indication for IVIG in immunocompromised patients with only decreased IgM and/or IgA levels?
In a patient with negative Hep B surface Ag, Hep B surface antibody+, and Hep B core antibody+ serologies, do you initiate antiviral prophylaxis (e.g. entecavir) prior to starting rituximab?
How do you manage recalcitrant tumid lupus in a patient with partial response to antimalarials and off-label apremilast, in the setting of coexisting MDS with significant neutropenia?
How would you counsel a patient with relapsing polychondritis who is considering a turbinectomy for nasal obstruction regarding potential risks and disease-related complications?
Can Xolair (omalizumab) be safely used in combination with biologics for patients with rheumatic disease?
What specific historical questions do you prioritize when evaluating hair loss to identify features suggestive of autoimmune or connective tissue disorders?